Welcome to our dedicated page for Dynavax Technologies Corporation news (Ticker: DVAX), a resource for investors and traders seeking the latest updates and insights on Dynavax Technologies Corporation stock.
Dynavax Technologies Corporation (Nasdaq: DVAX) is a prominent clinical-stage biopharmaceutical firm dedicated to developing innovative vaccines targeting infectious and inflammatory diseases, as well as cancer. With its headquarters in Emeryville, California, the company is renowned for leveraging the body's innate and adaptive immune responses through its proprietary Toll-like Receptor Immune Modulation Platform technology.
Core Products and Clinical Pipeline:
- HEPLISAV-B®: Approved in the U.S., EU, and Great Britain, HEPLISAV-B is the first and only adult hepatitis B vaccine that allows series completion with just two doses in one month. It continues to show strong market expansion and revenue growth.
- CpG 1018® Adjuvant: An essential component in multiple adjuvanted COVID-19 vaccines, this adjuvant enhances the immune response.
- Shingles Vaccine Program (Z-1018): In development for preventing shingles in adults aged 50 and older, promising robust immune responses.
- Tdap Vaccine Program (Tdap-1018): Focused on active booster immunization against tetanus, diphtheria, and pertussis.
- Plague Vaccine Program (DV2-PLG-01): In Phase 2 clinical trials, this program is fully funded by the U.S. Department of Defense.
Recent Achievements and Financial Highlights:
- Dynavax reported record revenue growth for HEPLISAV-B in 2023, capturing significant market share in the adult hepatitis B vaccine sector.
- As of December 31, 2023, the company had cash, cash equivalents, and marketable securities worth $742.3 million, underpinning its strong financial foundation.
- For the first quarter of 2024, Dynavax's net loss was reduced compared to the same period in 2023, due to improved operational efficiencies and strategic market initiatives.
Strategic Partnerships:
Collaborations with global biopharmaceutical companies, including AstraZeneca in Europe, further strengthen Dynavax's market position and broaden its product reach.
For detailed financial information and ongoing updates, investors can access the company's Events & Presentations page on their official website.
Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical firm focusing on vaccine development, announced that CEO Ryan Spencer will present at the Stifel 2020 Virtual Healthcare Conference on November 16 at 3:30 p.m. E.T. Investors can access the live audio webcast via the 'Events & Presentations' section on the company's website. A replay will be available for 30 days after the event. Dynavax's HEPLISAV-B® vaccine is approved for preventing hepatitis B in adults and is advancing its CpG 1018 vaccine adjuvant through various collaborations.
Dynavax Technologies Corporation (Nasdaq: DVAX) will report its third quarter 2020 financial results on November 5, 2020, after U.S. markets close. A conference call with live audio webcast is scheduled at 4:30 p.m. ET. The company is known for developing novel vaccines, including HEPLISAV-B®, a hepatitis B vaccine. Further developments include collaborations on adjuvanted vaccines targeting COVID-19 and influenza. For detailed information, visit www.dynavax.com.
Dynavax Technologies (DVAX) announced that Medigen Vaccine Biologics Corporation (MVC) received a Taiwan government subsidy of NT$ 472 million (US$ 16.4 million) for initiating a Phase 1 clinical trial of a COVID-19 vaccine. The trial, which started in early October, aims to evaluate the safety and immunogenicity of MVC's vaccine combined with Dynavax's CpG 1018 adjuvant. The study involves around 45 healthy participants, receiving two doses 28 days apart, demonstrating the potential for enhanced immune response against COVID-19.
Dynavax Technologies Corporation (NASDAQ: DVAX) announced the appointment of Peter R. Paradiso, Ph.D., to its Board of Directors on September 24, 2020. With over 30 years of expertise in vaccine strategic planning, Paradiso is set to provide valuable guidance as the company expands its vaccine portfolio, particularly focusing on HEPLISAV-B and CpG 1018. Concurrently, Michael Ostrach, CFO and CBO, has announced his retirement planned for 2021. Dynavax will seek a successor while Ostrach continues until March 31, 2021, to ensure a smooth transition.
Valneva SE and Dynavax Technologies Corporation have formed a commercial partnership for the supply of Dynavax's CpG 1018 adjuvant to be used in Valneva's COVID-19 vaccine candidate, VLA2001. The UK government has agreed to purchase up to 190 million doses of VLA2001 over five years. Dynavax will supply the adjuvant necessary for 100 million doses in 2021, with an option for an additional 90 million doses by 2025. VLA2001 is expected to enter clinical studies by the end of 2020 and aims for regulatory approval in the second half of 2021.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced that CEO Ryan Spencer will participate in a virtual fireside chat at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference on September 14, 2020, at 10:00 a.m. ET. The event will be accessible via a webcast on the company's website under the 'Events & Presentations' section. Dynavax is focused on developing novel vaccines, including its first commercial product, HEPLISAV-B®, launched in February 2018, aimed at preventing hepatitis B infections in adults.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced a $3.4 million grant from the Bill & Melinda Gates Foundation to scale up production of its CpG 1018 adjuvant, which supports COVID-19 vaccine development. This funding aims to increase manufacturing capacity to 750 million doses annually, potentially aiding global vaccine distribution. CEO Ryan Spencer emphasized the importance of adjuvants in enhancing vaccine effectiveness. CpG 1018 has a proven track record with the FDA-approved HEPLISAV-B hepatitis B vaccine.
Dynavax Technologies Corporation (DVAX) reported second quarter 2020 financial results, revealing net product revenue of $2.4 million, a decline from $8.3 million in Q2 2019, primarily due to a significant drop in adult hepatitis B vaccine utilization caused by the COVID-19 pandemic. Despite this setback, the company's prospects remain positive with ongoing collaborations to develop adjuvanted vaccines, including COVID-19. The net loss for the quarter was $51.6 million, or $0.53 per share, with a cash position of $200.7 million as of June 30, 2020.
Dynavax Technologies Corporation (Nasdaq: DVAX) will announce its second quarter 2020 financial results on August 6, 2020, after market close. A conference call and audio webcast will follow at 4:30 p.m. ET. The company, known for developing novel vaccines, launched HEPLISAV-B® in February 2018, and is advancing CpG 1018 as a vaccine adjuvant with partnerships focused on vaccines for COVID-19, pertussis, and universal influenza. Access to the webcast will be available on their website, with a replay for 30 days post-event.
Dynavax Technologies (Nasdaq: DVAX) announced the appointment of Julie Eastland and Brent MacGregor to its Board of Directors. Julie brings over 25 years of experience in financial roles within biotechnology, while Brent has 20 years in global strategy and commercial operations, particularly in vaccines. Both are expected to provide strategic insights to strengthen Dynavax's position in the vaccine market, building on their established products like HEPLISAV-B and CpG 1018.
FAQ
What is the current stock price of Dynavax Technologies Corporation (DVAX)?
What is the market cap of Dynavax Technologies Corporation (DVAX)?
What is Dynavax Technologies Corporation known for?
What are the key products of Dynavax?
What is HEPLISAV-B®?
What is the significance of the CpG 1018® adjuvant?
Who are Dynavax's key partners?
What are the recent financial highlights of Dynavax?
What is the clinical pipeline focus of Dynavax?
How does Dynavax plan to sustain its growth?
How can investors get updates on Dynavax?
What are the most common adverse reactions to HEPLISAV-B?
